12 results on '"Elias Athanasiadis"'
Search Results
2. Treatment pathways and associated costs of metastatic colorectal cancer in Greece
- Author
-
Ioannis Sougklakos, Elias Athanasiadis, Ioannis Boukovinas, Michalis Karamouzis, Aggelos Koutras, Paulos Papakotoulas, Dimitra Latsou, Magda Hatzikou, Eugena Stamuli, Athanasios Balasopoulos, and Aggelos Sideris
- Subjects
Metastatic colorectal cancer ,Braf600 mutation ,Disease burden ,Treatment pathways ,Costs ,Greece ,Medicine (General) ,R5-920 - Abstract
Abstract Objectives Colorectal cancer (CRC) is the second leading cause of cancer in Europe, with 1.931.590 people newly diagnosed in 2020. The purpose of this study is the investigation of treatment options and healthcare resource metastatic CRC (mCRC) in Greece. Methods This study is based on the information collected in November 2020 by an expert panel comprising of 6 medical oncologists from major public and private centers around Greece. A 3-round survey was undertaken, according to Delphi method. The treatment phases studied were: pre-progression; disease progression and terminal care. Pharmaceutical costs and resource utilization data were considered from the perspective of the Greek National Services Organization (EOPYY). RESULTS: Experts agreed that the anticipated prevalence of RAS mutation in mCRC is 47% (30% RAS/BRAF WT Left, 17% RAS/BRAF WT Right); 8% BRAF while, MSI-H/dMMR are found in 5% of mCRC tumors. Based on mutational status, 74.8% of patients receive biological targeted therapies in combination with fluoropyrimidine/based combination chemotherapy, as 1st line treatment, and 25.2% combination chemotherapy alone. At 2nd line, 58.6% of patients receive biological targeted therapies in combination with chemotherapy, 25.4% immunotherapy, 11% combination chemotherapy and 5% biological targeted therapies. At 3rd line 56% of patients receive combination chemotherapy, 28% biological targeted therapies, 10% biological targeted therapies in combination with chemotherapy and 6% immunotherapy. The weighted annual cost (pharmaceuticals and resource use cost) in 1st line per mCRC patient was calculated at €28,407, in 2nd line €33,568, in 3rd line €25,550. The annual cost beyond 3rd line per patient regardless mutation was €19,501 per mCRC patient. Conclusions mCRC is a societal challenge for healthcare systems as the treatment is more prolonged but expand patients’ survival. Thus, reimbursement decisions should be based not just on the cost of the treatment, but on the magnitude of the benefit of its treatment on patients’ survival and quality of life.
- Published
- 2022
- Full Text
- View/download PDF
3. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
- Author
-
Eirini Papadopoulou, Nikolaos Tsoulos, Katerina Tsantikidi, Vasiliki Metaxa-Mariatou, Pinelopi Eleftheria Stamou, Athina Kladi-Skandali, Evgenia Kapeni, Georgios Tsaousis, George Pentheroudakis, Dimitrios Petrakis, Dimitra Ioanna Lampropoulou, Gerasimos Aravantinos, Ioannis Varthalitis, George Kesisis, Ioannis Boukovinas, Pavlos Papakotoulas, Nikolaos Katirtzoglou, Elias Athanasiadis, Flora Stavridi, Christos Christodoulou, Anna Koumarianou, Yeşim Eralp, and George Nasioulas
- Subjects
Medicine ,Science - Abstract
BackgroundAnalysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form of "liquid biopsy" and provides real-time information on the molecular profile of the tumor without an invasive tissue biopsy.MethodsLiquid biopsy analysis was requested by the referral physician in 121 NSCLC patients at diagnosis and was performed using a sensitive Next Generation Sequencing assay. Additionally, a comparative analysis of NSCLC patients at relapse following EGFR Tyrosine Kinase Inhibitor (TKIs) treatment was performed in 50 patients by both the cobas and NGS platforms.ResultsAt least one mutation was identified in almost 49% of the cases by the NGS approach in NSCLC patients analyzed at diagnosis. In 36 cases with paired tissue available a high concordance of 86.11% was observed for clinically relevant mutations, with a Positive Predictive Value (PPV) of 88.89%. Furthermore, a concordance rate of 82% between cobas and the NGS approach for the EGFR sensitizing mutations (in exons 18, 19, 21) was observed in patients with acquired resistance to EGFR TKIs, while this concordance was 94% for the p.T790M mutation, with NGS being able to detect this mutation in three 3 additional patients.ConclusionsThis study indicates the feasibility of circulating tumor nucleic acids (ctNA) analysis as a tumor biopsy surrogate in clinical practice for NSCLC personalized treatment decision making. The use of new sensitive NGS techniques can reliably detect tumor-derived mutations in liquid biopsy and provide clinically relevant information both before and after targeted treatment in patients with NSCLC. Thus, it could aid physicians in treatment decision making in clinical practice.
- Published
- 2019
- Full Text
- View/download PDF
4. Athenian University Students on Facebook and Privacy: A Fair 'Trade-Off '?
- Author
-
Stylianos Papathanassopoulos, Elias Athanasiadis, and Maria Xenofontos
- Subjects
Communication. Mass media ,P87-96 - Abstract
This article explores how Athenian university students “manage” their privacy on Facebook while socially interacting with other users. Survey data of undergraduate students in Athens reveal that the social network site use “validates” and enhances the pre-existing social context and that the relationship level has an impact on the way users contact other users on it. We find that Facebook users feel that they are able to use most of the privacy settings to protect their personal data. Yet, they are concerned about the disclosure of their personal information which is perceived to be their primary responsibility. Despite these concerns, they appear to feel in control of their privacy through the abilities they are offered by the social networking site (SNS). We also argue that even if they realize that they are disclosing their personal information, this doesn’t cause a great deal of insecurity.
- Published
- 2016
- Full Text
- View/download PDF
5. Clinical Outcomes Beyond 1LEGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study ‘LUNGFUL’
- Author
-
GIANNIS MOUNTZIOS, ANNA KOUMARIANOU, HELENA LINARDOU, ANASTASIOS BOUTIS, DIMITRIOS MAVROUDIS, EPAMINONDAS SAMANTAS, IPPOKRATIS KORANTZIS, ELIAS ATHANASIADIS, EVANGELOS G. FERGADIS, SOFIA LAMPAKI, VASSILIS GEORGOULIAS, SOFIA BAKA, MICHALIS V. KARAMOUZIS, IOANNIS BOUKOVINAS, CHARALAMPOS ANDREADIS, AGGELIKI RAPTI, NIKOLAOS KOULOURIS, GEORGE PENTHEROUDAKIS, MARIOS E. FROUDARAKIS, ALVERTOS SOMARAKIS, ELEFTHERIA ANASTASOPOULOU, ALEXANDRA KARADIMOU, FOTEINI PAPAGEORGIOU, ZOE PAPAREPA, ARISTEIDIS NIKOLAOU, CHRISTINA PAPISTA, and KONSTANTINOS N. SYRIGOS
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2023
6. Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece
- Author
-
Sofia Lampaki, Giannis Mountzios, Vassilis Georgoulias, Aggeliki Rapti, Ioannis Xanthakis, Sofia Baka, Dimitrios Mavroudis, Epaminondas Samantas, Elias Athanasiadis, Flora Zagouri, Andriani Charpidou, Alvertos Somarakis, Christina Papista, Aristeidis Nikolaou, Eleftheria Anastasopoulou, Zoe Paparepa, and Konstantinos N Syrigos
- Subjects
Cancer Research ,Oncology ,General Medicine - Abstract
Aim: To retrospectively characterize real-world therapeutic strategies, clinical outcomes and attrition rates with EGFR tyrosine kinase inhibitors (TKIs), before first-line osimertinib approval, in EGFR-mutated advanced/metastatic non-small-cell lung cancer patients in Greece. Results: Among 160 patients, the discontinuation rate for first-line first- or second-generation EGFR-TKIs was 85%; among these patients, 43% did not receive any second-line therapy and 9.4% died during an 18.7-month follow-up period. Median progression-free and overall survival were 12.1 and 20.9 months, respectively. Osimertinib was offered as second- and third-line treatment in 69.6 and 21.7% of patients with the T790M mutation, respectively. Brain metastases were recorded in 10.6% of patients during treatment, with median overall survival of 4.9 months. Conclusion: Given the high attrition rates and the impact of CNS progression, offering the most appropriate first-line EGFR-TKI treatment with CNS penetration is key to maximize outcomes.
- Published
- 2022
7. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study
- Author
-
Anna Koumarianou, Giannis Mountzios, Sofia Lampaki, Alexandros Bokas, Aristeidis Nikolaou, Helena Linardou, Konstantinos N. Syrigos, Epaminondas Samantas, Michalis V. Karamouzis, George Pentheroudakis, Elias Athanasiadis, Zoe Paparepa, Dimitrios Mavroudis, Alvertos Somarakis, Marios Froudarakis, Panagiotis Katsaounis, Eleni-Isidora A. Perdikouri, Foteini Papageorgiou, and Evangelos Georgios Fergadis
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,EGFR-tyrosine kinase inhibitor ,ECOG Performance Status ,carcinoma ,Article ,03 medical and health sciences ,T790M ,0302 clinical medicine ,Cytology ,Internal medicine ,Biopsy ,medicine ,Carcinoma ,biopsy ,Epidermal growth factor receptor ,Prospective cohort study ,Lung cancer ,RC254-282 ,medicine.diagnostic_test ,biology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,respiratory tract diseases ,030104 developmental biology ,non-small-cell lung cancer ,T790M mutation ,030220 oncology & carcinogenesis ,biology.protein ,business ,epidermal growth factor receptor - Abstract
Simple Summary Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, with few patients carrying driver mutations in the gene encoding for epidermal growth factor receptor (EGFR). Advances in translational research have established EGFR tyrosine kinase inhibitors (TKIs) as the standard first-line therapy for NSCLC patients with activating EGFR mutations. The aim of our observational study was to assess the frequency of T790M acquired resistance and predictors of its presence, in patients with EGFR-mutated locally advanced or metastatic NSCLC who have progressed in the first-line EGFR-TKI treatment setting with first- or second-generation TKIs and have undergone molecular testing in tissue and/or plasma biopsy. The study highlights the challenges of performing tissue re-biopsy in routine care settings, which can lead to patients considered non-eligible for certain therapies from which they can benefit, and merits further actions from the healthcare community, in order to establish re-biopsy as a standard procedure. Abstract Background: Real-world data on the molecular epidemiology of EGFR resistance mutations at or after progression with first- or second-generation EGFR-TKIs in patients with advanced NSCLC are lacking. Methods: This ongoing observational study was carried out by 23 hospital-based physicians in Greece. The decision to perform cobas® EGFR Mutation Test v2 in tissue and/or plasma at disease progression was made before enrollment. For patients with negative/inconclusive T790M plasma-based results, tissue re-biopsy could be performed. Results: Ninety-six (96) eligible patients were consecutively enrolled (median age: 67.8 years) between July-2017 and September-2019. Of the patients, 98% were tested upon progression using plasma and 2% using tissue/cytology biopsy. The T790M mutation was detected in 16.0% of liquid biopsies. Tissue re-biopsy was performed in 22.8% of patients with a T790M-negative plasma result. In total, the T790M positivity rate was 21.9%, not differing between patients on first- or second-generation EGFR-TKI. Higher (≥2) ECOG performance status and longer (≥10 months) time to disease progression following EGFR-TKI treatment initiation were associated with T790M positivity. Conclusions: Results from plasma/tissue-cytology samples in a real-world setting, yielded a T790M positivity rate lower than previous reports. Fewer than one in four patients with negative plasma-based testing underwent tissue re-biopsy, indicating the challenges in routine care settings.
- Published
- 2021
8. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ Study
- Author
-
Helena Linardou, Epaminondas Samantas, Elias Athanasiadis, Alexandros Bokas, Marios Froudarakis, Sofia Lampaki, Foteini Papageorgiou, Anna Koumarianou, George Pentheroudakis, Michalis V. Karamouzis, Eleni-Isidora A. Perdikouri, Giannis Mountzios, Dimitrios Mavroudis, Alvertos Somarakis, Aristeidis Nikolaou, Evangelos Georgios Fergadis, Panagiotis Katsaounis, Zoe Paparepa, and Konstantinos N. Syrigos
- Subjects
Oncology ,medicine.medical_specialty ,Molecular epidemiology ,biology ,medicine.diagnostic_test ,business.industry ,allergology ,ECOG Performance Status ,medicine.disease ,respiratory tract diseases ,T790M ,Internal medicine ,Cytology ,Biopsy ,medicine ,biology.protein ,Epidermal growth factor receptor ,Lung cancer ,Prospective cohort study ,business - Abstract
Background: Real-world data on the molecular epidemiology of EGFR resistance mutations at or after progression with first- or second-generation EGFR-TKIs in patients with advanced NSCLC are lacking. Methods: This ongoing observational study was carried out by 23 hospital-based physicians in Greece. The decision to perform Cobas® EGFR Mutation Test v2 in tissue and/or plasma at disease progression was made before enrollment. For patients with negative/inconclusive T790M plasma-based results, tissue re-biopsy could be performed. Results: Ninety-six (96) eligible patients were consecutively enrolled (median age: 67.8 years) between July-2017 and September-2019. Of the patients, 98% were tested upon progression using plasma and 2% using tissue/cytology biopsy. The T790M mutation was detected in 16.0% of liquid biopsies. Tissue re-biopsy was performed in 22.8% of patients with a T790M-negative plasma result. In total, the T790M positivity rate was 21.9%, not differing between patients on first- or second-generation EGFR-TKI. Higher (≥2) ECOG performance status and longer (≥10 months) time to disease progression following EGFR-TKI treatment initiation were associated with T790M positivity. Conclusions: Results from plasma/tissue-cytology samples in a real-world setting, yielded a T790M positivity rate lower than previous reports. Fewer than one in four patients with negative plasma-based testing underwent tissue re-biopsy, indicating the challenges in routine care settings.
- Published
- 2021
9. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
- Author
-
Nikolaos Tsoulos, P. Papakotoulas, George Nasioulas, Evgenia Kapeni, Pinelopi Eleftheria Stamou, Vasiliki Metaxa-Mariatou, Dimitra Ioanna Lampropoulou, George Kesisis, Katerina Tsantikidi, Christos Christodoulou, Dimitrios Petrakis, Georgios N. Tsaousis, Yesim Eralp, Ioannis Boukovinas, Eirini Papadopoulou, Gerasimos Aravantinos, George Pentheroudakis, Flora Stavridi, Ioannis Varthalitis, Nikolaos Katirtzoglou, Anna Koumarianou, Elias Athanasiadis, and Athina Kladi-Skandali
- Subjects
0301 basic medicine ,Oncology ,Male ,Lung Neoplasms ,Molecular biology ,Biopsy ,Mutagenesis and Gene Deletion Techniques ,Gene Identification and Analysis ,Cancer Treatment ,Drug resistance ,Biochemistry ,Lung and Intrathoracic Tumors ,Circulating Tumor DNA ,0302 clinical medicine ,Sequencing techniques ,Carcinoma, Non-Small-Cell Lung ,Medicine and Health Sciences ,DNA sequencing ,Precision Medicine ,Aged, 80 and over ,Multidisciplinary ,medicine.diagnostic_test ,High-Throughput Nucleotide Sequencing ,Genomics ,Exons ,Middle Aged ,Clinical Practice ,ErbB Receptors ,030220 oncology & carcinogenesis ,Medicine ,Female ,Transcriptome Analysis ,Research Article ,Next-Generation Sequencing ,Adult ,medicine.medical_specialty ,Concordance ,Science ,Clinical Decision-Making ,Surgical and Invasive Medical Procedures ,03 medical and health sciences ,Text mining ,Internal medicine ,medicine ,Carcinoma ,Genetics ,Biomarkers, Tumor ,Humans ,Liquid biopsy ,Mutation Detection ,Protein Kinase Inhibitors ,Aged ,business.industry ,Liquid Biopsy ,Biology and Life Sciences ,Cancers and Neoplasms ,Computational Biology ,medicine.disease ,Genome Analysis ,Non-Small Cell Lung Cancer ,respiratory tract diseases ,Research and analysis methods ,030104 developmental biology ,Molecular biology techniques ,Mutational Analysis ,Drug Resistance, Neoplasm ,Mutation ,Feasibility Studies ,Molecular Profile ,Neoplasm Recurrence, Local ,business ,Biomarkers - Abstract
BackgroundAnalysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form of "liquid biopsy" and provides real-time information on the molecular profile of the tumor without an invasive tissue biopsy.MethodsLiquid biopsy analysis was requested by the referral physician in 121 NSCLC patients at diagnosis and was performed using a sensitive Next Generation Sequencing assay. Additionally, a comparative analysis of NSCLC patients at relapse following EGFR Tyrosine Kinase Inhibitor (TKIs) treatment was performed in 50 patients by both the cobas and NGS platforms.ResultsAt least one mutation was identified in almost 49% of the cases by the NGS approach in NSCLC patients analyzed at diagnosis. In 36 cases with paired tissue available a high concordance of 86.11% was observed for clinically relevant mutations, with a Positive Predictive Value (PPV) of 88.89%. Furthermore, a concordance rate of 82% between cobas and the NGS approach for the EGFR sensitizing mutations (in exons 18, 19, 21) was observed in patients with acquired resistance to EGFR TKIs, while this concordance was 94% for the p.T790M mutation, with NGS being able to detect this mutation in three 3 additional patients.ConclusionsThis study indicates the feasibility of circulating tumor nucleic acids (ctNA) analysis as a tumor biopsy surrogate in clinical practice for NSCLC personalized treatment decision making. The use of new sensitive NGS techniques can reliably detect tumor-derived mutations in liquid biopsy and provide clinically relevant information both before and after targeted treatment in patients with NSCLC. Thus, it could aid physicians in treatment decision making in clinical practice.
- Published
- 2019
10. Abstract P3-09-01: A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive breast
- Author
-
Nikolaos Kentepozidis, Nikolaos Ziras, Nikolaos A. Malamos, Dimitrios Mavroudis, Stylianos Kakolyris, Vassilis Georgoulias, P. Papakotoulas, Elias Athanasiadis, Kostas Kalbakis, Charalambos Christophyllakis, and Ioannis Boukovinas
- Subjects
Cancer Research ,Chemotherapy ,medicine.medical_specialty ,Taxane ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,medicine.disease ,Gastroenterology ,Surgery ,Regimen ,Breast cancer ,Oncology ,Docetaxel ,Internal medicine ,medicine ,Adjuvant therapy ,business ,medicine.drug ,Epirubicin - Abstract
Background: The dose dense sequential administration of anthracycline and taxane is very effective as adjuvant therapy in node-positive early breast cancer. The non-anthracycline regimen docetaxel plus cyclophosphamide (TC regimen) was better than four cycles of doxorubicin/cyclophosphamide as adjuvant therapy. This study compared the dose dense sequential regimen versus the TC regimen as adjuvant therapy. Methods: Women with axillary node-positive, HER2-negative early breast cancer were randomized following surgery to receive either dose dense G-CSF-supported FEC (5FU 500mg/m2, epirubicin 75mg/m2, cyclophosphamide 500mg/m2 every 14 days for 4 cycles) followed by Docetaxel (75mg/m2 every 14 days for 4 cycles) (arm A) or 6 cycles of Docetaxel 75mg/m2 plus Cyclophospamide 600mg/m2 every 3 weeks (arm B). The primary endpoint of the study was the 3-year disease-free survival (DFS). Results: Six hundred fifty patients were randomized; 326 on arm A and 324 on arm B. Of them 109 (33%) and 90 (28%) were premenopausal, 196 (60%) and 218 (67%) had 1-3 positive nodes, 284 (87%) and 288 (89%) were hormone receptor positive in arm A and B, respectively. Chemotherapy was completed in 97% and 93% of patients in arm A and B, respectively. After a median follow up of 46 and 47 months, there were 37 (11.3%) and 33 (10.1%) disease relapses and the median DFS has not yet been reached (p=0.5) while the 3-year DFS rate was 89.5% and 91.1% for arm A and B, respectively. Neutropenia grade III-IV was more common in arm B and anemia, nausea, vomiting and fatigue grade II-III in arm A. No toxic deaths occurred. Conclusions: The 3-year DFS rate was similar between the dose dense sequential FEC/docetaxel combination and the TC regimen in women with node-positive HER2-negative early breast cancer. Citation Format: Dimitrios Mavroudis, Nikolaos Malamos, Pavlos Papakotoulas, Stylianos Kakolyris, Ioannis Boukovinas, Elias Athanasiadis, Nikolaos Kentepozidis, Nikolaos Ziras, Kostas Kalbakis, Charalambos Christophyllakis, Vassilis Georgoulias. A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive breast [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-09-01.
- Published
- 2015
11. Tumor molecular profiling of NSCLC patients using next generation sequencing
- Author
-
Vasiliki Metaxa-Mariatou, Elias Athanasiadis, Eugenia Bourkoula, Aikaterini Scapeti, Nikolaos Tsoulos, Stylianos Kakolyris, George Nasioulas, George Pentheroudakis, Chrisoula Efstathiadou, Anca Dinischiotu, Eirini Papadopoulou, Theofanis Floros, Vasileios Barbounis, Georgia Tounta, Georgios N. Tsaousis, P. Papakotoulas, Anna Koumarianou, Ioannis Boukovinas, and P. Zarogoulidis
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Biology ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,ROS1 ,Humans ,Gene Regulatory Networks ,Genetic Predisposition to Disease ,Molecular Targeted Therapy ,Lung cancer ,Gene ,Allele frequency ,non-small cell lung cancer ,next generation sequencing ,Oncogene ,Point mutation ,predictive markers ,High-Throughput Nucleotide Sequencing ,Articles ,Sequence Analysis, DNA ,General Medicine ,targeted therapy ,medicine.disease ,Molecular medicine ,3. Good health ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Female - Abstract
Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with a broad spectrum of targeted therapies already available or in clinical trials. Thus, molecular characterization of the tumor using next generation sequencing (NGS) technology, has become a key tool for facilitating treatment decisions and the clinical management of NSCLC patients. The performance of a custom 23 gene multiplex amplification hot spot panel, based on Ion AmpliSeq™ technology, was evaluated for the analysis of tumor DNA extracted from formalin-fixed and paraffin-embedded (FFPE) tissues. Furthermore, the Ion AmpliSeq™ RNA Fusion Lung Cancer Research Panel was used for fusion RNA transcript analysis. The mutation spectrum of the tumors was determined in a cohort of 502 patients with NSCLC using the aforementioned targeted gene panels. The panel used for tumor DNA analysis in this study exhibited high rates (100%) of sensitivity, specificity and reproducibility at a mutation allelic frequency of 3%. At least one DNA mutation was detected in 374 patients (74.5%) and an RNA fusion was identified in 16 patients, (3.2%). In total, alterations in a cancer-driver gene were identified (including point mutations, gene rearrangements and MET amplifications) in 77.6% of the tumors tested. Among the NSCLC patients, 23% presented a mutation in a gene associated with approved or emerging targeted therapy. More specifically, 13.5% (68/502) presented a mutation in a gene with approved targeted therapy (EGFR, ALK, ROS1) and 9.4% (47/502) had an alteration in a gene related to emerging targeted therapies (ERBB2, BRAF, MET and RET). Furthermore, 51.6% of the patients had a mutation in a gene that could be related to an off label therapy or indicative for access to a clinical trial. Thus, the targeted NGS panel used in this study is a reliable approach for tumor molecular profiling and can be applied in personalized treatment decision making for NSCLC patients.
- Published
- 2017
12. Athenian University Students on Facebook and Privacy: A Fair 'Trade-Off '?
- Author
-
Maria Xenofontos, Elias Athanasiadis, and Stylianos Papathanassopoulos
- Subjects
Cultural Studies ,Cyberpsychology ,business.industry ,Communication ,05 social sciences ,Internet privacy ,050301 education ,050801 communication & media studies ,lcsh:P87-96 ,Computer Science Applications ,lcsh:Communication. Mass media ,0508 media and communications ,Fair trade ,Survey data collection ,Social media ,Sociology ,business ,0503 education ,Social capital - Abstract
This article explores how Athenian university students “manage” their privacy on Facebook while socially interacting with other users. Survey data of undergraduate students in Athens reveal that the social network site use “validates” and enhances the pre-existing social context and that the relationship level has an impact on the way users contact other users on it. We find that Facebook users feel that they are able to use most of the privacy settings to protect their personal data. Yet, they are concerned about the disclosure of their personal information which is perceived to be their primary responsibility. Despite these concerns, they appear to feel in control of their privacy through the abilities they are offered by the social networking site (SNS). We also argue that even if they realize that they are disclosing their personal information, this doesn’t cause a great deal of insecurity.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.